Frontiers in Clinical Drug Research - Anti-Cancer Agents: Volume 4 E-Book
73,52 €
Mehr erfahren.
- Herausgeber: Bentham Science Publishers
- Kategorie: Wissenschaft und neue Technologien
- Serie: Frontiers in Clinical Drug Research - Anti-Cancer Agents
- Sprache: Englisch
Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology researchers.
The fourth volume of the book brings forth reviews on biomarkers and new drugs used for treating gastrointestinal cancer and breast cancer. The volume also covers the topics of adjuvant therapy, cancer nanodrugs and the role of adiponectin and dicycloplatin in cancer therapy.
Sie lesen das E-Book in den Legimi-Apps auf:
Seitenzahl: 756
Veröffentlichungsjahr: 2017
Ähnliche
Frontiers in Clinical Drug
Research - Anti-Cancer Agents
(Volume 4)
Edited By
BENTHAM SCIENCE PUBLISHERS LTD
End User License Agreement (for non-institutional, personal use)
This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“Work”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.
Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [email protected].
Usage Rules:
All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it. The following DRM (Digital Rights Management) policy may also be applicable to the Work at Bentham Science Publishers’ election, acting in its sole discretion:25 ‘copy’ commands can be executed every 7 days in respect of the Work. The text selected for copying cannot extend to more than a single page. Each time a text ‘copy’ command is executed, irrespective of whether the text selection is made from within one page or from separate pages, it will be considered as a separate / individual ‘copy’ command.25 pages only from the Work can be printed every 7 days.3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.
Disclaimer:
Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.
Limitation of Liability:
In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.
General:
Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.Bentham Science Publishers Ltd. Executive Suite Y - 2 PO Box 7917, Saif Zone Sharjah, U.A.E. Email: [email protected]
PREFACE
Frontiers in Clinical Drug Research - Anti-Cancer Agents presents on recent developments in various therapeutic approaches against different types of cancer. The book is a valuable resource for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for devising research plans in anti-cancer research and developing clinical trials.
The chapters are written by authorities in the field. The contents of this volume represent exciting recent researches on advanced gastrointestinal cancers, breast cancer, cancer chemo-prevention and treatment, clinical anticancer nanodrug, adiponectin-based therapeutics, cancer vaccines, and chemotherapy medication. I hope that the readers will find these reviews valuable and thought provoking so that they may trigger further research in the quest for the new and novel therapies against cancers.
I am grateful for the timely efforts made by the editorial personnel, especially Mr. Mahmood Alam (Director Publications), and Mr. Shehzad Naqvi (Senior Manager Publications) at Bentham Science Publishers.
List of Contributors
Biomarkers for Monitoring Response to Therapies and Detection of Acquired Resistance in Advanced Gastrointestinal Cancers
Jens C. Hahne1,*, °,Milko Mirchev2, °,Iskren Kotzev2,Andrea Lampis1,Nicola Valeri1,3Abstract
Gastrointestinal cancers are among the most common causes of cancer-related death in the world. Alone the subgroup of colorectal cancer is the third most common cancer in men (746,000 new diagnosed cases in 2012, 10.0% of all cancer cases) and the second in women (614,000 new diagnosed cases in 2012, 9.2% of all cancer cases) worldwide. Beside different treatment strategies including surgery, radiotherapy and/or chemotherapy have improved the survival of patients in the last years, there is still an urgent need to improve prognosis in advanced disease by means of targeted therapies as well as an early detection of development of acquired resistance. For this purpose, molecular biomarkers are a promising option especially in the light of increasing amount of personalized medicine.
In this chapter, we will review classic biomarkers for prognosis already in clinical use (e.g. carcinoembriogenic antigen, cancer antigen 19-9, serum pepsinogen I, α-fetoprotein, CD117) and new ones with their usefulness following combined therapeutic regimens. Some new technologies like the very sensitive digital-droplet-PCR, next-generation sequencing and high-throughput screening methods for RNA expression patterns will be discussed shortly regarding their application for detecting and discovering potential new biomarkers. Finally, possible new potential mechanisms of resistance related to targeted pathways will be discussed as genetic and epigenetic alterations (hypermethylation of CpG-islands, copy-number variation, lncRNAs and single nucleotide polymorphisms). Furthermore, the potential of circulating tumour DNA and non-coding RNAs, with a special focus on microRNAs as new biomarkers will be addressed.
Introduction
Gastrointestinal (GI) cancer summarizes a diverse group of cancers that affect the digestive tract system [1, 2]. This includes cancers of the oesophagus, gallbladder, liver and biliary tract, pancreas, stomach, small intestine, large bowel (colon and rectum) and anus (Table 1).
GI cancer is the most common form of cancer responsible for nearly 25% of all new cancer diagnosis and responsible for most of cancer related death (around 30% of all cancer related death) worldwide [3, 4].
Clinical approaches for the treatment of GI cancers depend not only of cancer site but also on its clinicopathological stage or its development, and other patient-related factors. Treatment commonly includes surgery, chemotherapy and radiation therapy [5-13]. Even though these treatments over the last years have helped to prolong patients` survival, there is still an urgent need to provide a better prognosis particularly in advanced disease by means of targeted therapies as well as identify early biomarkers to overcome development of acquired resistance to treatment. Furthermore, the number of patients with metachronous metastatic disease, especially brain metastasis, is increasing caused by the therapeutical success and the longer survival of GI cancer patients [14-17]. This event represents another challenge that clinicians must deal for the treatment of GI cancer patients.
Molecular biomarkers might represent a promising and convenient option for patients` stratification that could help to provide a better treatment of GI cancer patients especially in the light of increasing amount of personalized medicine.
Source and Type of Biomarkers
Tissue and Blood Derived Biomarkers
In the discovery phases for both diagnostic and prognostic setting, several studies have attempted to identify molecular biomarkers by using primary lesions as source of information of molecular aberrations (both genetic and genomic) and correlate this information with clinical assessment of the patients` [18, 19]. For instance in colorectal cancer (CRC) common genetic features as mutations in Adenomatous Polyposis Coli (APC), Tumour Protein 53 (TP53), Kirsten Rat Sarcoma (KRAS), and V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) have been investigated for their potential usefulness as prognostic and predictive factors in early as well as advanced cancers [20, 21]. KRAS and BRAF are well known oncogenes mutated in a consistent proportion of CRC (40% and 8-10%, respectively) [22]. APC and TP53 on the contrary are important tumour suppressors and they are also highly mutated in CRC [23]. Early studies focused on detection of genetic DNA-based biomarkers to potentially identify prognostic and predictive markers [24]. In addition, recently also RNA molecules (mRNAs, microRNAs, lncRNAs) have been investigated for the same purposes [25-27]. Availability of primary cancer tissues has also allowed to identify protein biomarkers mainly trough immunostaining of known deregulated proteins [28]. However, due to the heterogeneous mutational spectrum of cancers, multiple assays need to be tested and developed in order to improve sensitivity. Furthermore, it becomes evident that assessment of primary cancer does not necessary reflect the mutational status in metastatic disease [29]. Minimally invasive approaches as blood-based test to assess genomic, trascriptomic and proteomic markers on the contrary not only improve the patient’s compliance over biopsy-based tissue recovery but also the genomic abnormalities characteristic of Specific GI cancers might be better represented and thus allowing an improved cancer monitoring capability.
Protein Based Versus DNA and RNA Based Biomarkers
Proteomic technologies are generally used to discover and measure protein expression levels and have the potential to be used for developing new panels of biomarkers. In diagnostic settings several blood tests are presently used for monitoring cancer recurrence and prognosis. These tests detect the tumour markers carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), septin-9 (SEPT9), tissue polypeptide specific antigen (TPS) or tumour-associated glycoprotein-72 (TAG72) [30-33]. For instance CEA is knowingly elevated in blood of patients with colorectal cancer and others GI cancers [34]. However, its low sensitivity (5-10%) precludes its use for an early detection of cancer but blood over-expression has been used for monitor the disease and as prognostic factor [35, 36]. CA19-9 is a blood antigen that is found generally elevated in colorectal cancers but also other GI cancers [34, 37]. Nevertheless, it has been shown that CA19-9 is not very specific for tumour type and furthermore it has been found less sensitive than CEA [37]. Moreover, both biomarkers are significantly elevated in patients with metastatic disease but not in early cancer thus resulting not useful for diagnostic purposes [31]. Another possible biomarker test is the analyse of SEPT9 methylated DNA in serum [38] but once again this test has a moderate sensitivity (70%) and specificity (90%) [39]. TPS level in the blood indicates the tumour proliferation rate but with a diagnostic sensitivity around 58% it has only very limited importance as tumour marker [40]. The glycoprotein TAG72 can be measured in blood samples but it is not specific for GI cancer [41-43] and furthermore TAG72 protein level are found to be increased more frequently in poorly-differentiated tumours than in well-differentiated cancers [44].
New proteomic technologies like two-dimensional electrophoresis (2-DE) and two-dimensional differential in-gel electrophoresis (2D-DIGE) [45] but also the surface-enhanced laser desorption/ionization time of-flight mass spectrometry (SELDI-TOF-MS) or the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) [46] techniques are evolving as tools for new biomarker discovery. However, the main protein or metabolites derived biomarkers studied appear to be not enough sensitive or specific thus being unable to substitute already validated and used clinical tests is mainly for poor study design or experimental output validation [47]. The advantage of DNA and RNA, especially microRNA, based biomarkers is provided not only in higher stability in body fluids like blood, serum, plasma, urine but also in better specificity given the genomic make-up characteristic of many cancers [48, 49]. Evidence for nucleic acid based biomarkers is emerging during last decade through studies employing new technologies as next-generation sequencing (NGS) [50]. For instance, for colorectal cancer, most of the recent proposed prognostic tests are gene expression-based panels established on RNA from cancer tissue, for detection of potential recurrence like Oncotype DX Colon Cancer, GeneFx Colon, Coloprint, ColoGuideEx, OncoDefender-CRC, CologuidePro [51]. Nevertheless, another issue as preparation of the samples, storage and method of extraction for both proteomic and genomic-trancriptomic analyses are essential and might introduce technical bias that might affect a proper biomarker discovery and/or validation.
New Potential Biomarkers
Circulating Free Tumour DNA (cft-DNA)
In the last few years a lot of research has been focussed on the potential use of circulating DNA derived from tumour cells (cft-DNA). Fragmented DNA from cells is released into the blood stream following cell death [52-55]. Cft-DNA is relatively stable in blood and can be isolated as a derivation from serum or plasma both manually and with automated technologies [53]. Therefore, analysis of cft-DNA from blood -the so-called liquid biopsies- could represent a minimal-invasive method for monitoring the disease and implement the design of a therapeutic strategy as well as to assess the Advent of a potential drug resistance [54]. Furthermore, it has the benefit to increase patients`compliance as well as reducing the tumour biopsies-related risks for the patient. Another important advantage is that cft-DNA isolated from the blood might represent better the intra-tumour heterogeneity than needle biopsy [56-58]. It has been proposed that a tumour mass can contain heterogeneous-cell populations with diverse molecular backgrounds and also between primary tumour and metastatic sites often genetic differences are observed [59, 60]. The use of cft-DNA isolated from blood overcomes the limitations of tumour biopsies which are also restricted to the sampling of a small part of a specific reachable tumour side.
For instance, by using ddPCR for analyzing cft-DNA resulted in a powerful method to monitor therapy response as well as disease progression of cancer patients [61, 62]. It has been shown that it was possible to detect gene specific mutations that are known to be associated with tumour progression several months before tumour progression was radiological assessed [63, 64].
Circulating Non-coding RNAs: MicroRNAs and lncRNAs
Another current focus of research is the use of non-coding RNA as new biomarkers [65-67]. Non-coding RNAs are a large family of RNA molecules that includes transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), small nucleolar RNAs (snoRNAs), microRNA, small interfering RNA (siRNAs), small nuclear RNA (snRNAs), extracellular RNA (exRNAs), piwi-interacting RNA (piRNAs), small Cajal body RNA (scaRNAs) and long non-coding RNA (lncRNA), all of which are not coding for known proteins [66, 68-80]. Today lncRNAs are recognized and accepted as important regulators during development and pathological processes [81-85]. LncRNAs are involved in regulating gene expression by binding to chromatin regulatory proteins and they are able to alter chromatin modification as well as transcriptional or posttranscriptional gene regulation by interacting with other RNAs and proteins [70]. Recently, a crosstalk and strong linkage between lncRNA and microRNAs has been identified [86]. Sometimes lncRNA stability can be reduced by interaction with specific microRNAs but it is also possible that lncRNAs act as microRNA decoys resulting in sequestering microRNAs and leading by this to expression of the microRNA target genes [86]. Furthermore, lncRNAs can favour gene expression by competing with microRNAs for specific binding sites in the non-coding regions of mRNAs and prevent the transcriptional repression caused by microRNA binding [86]. Surprisingly some lncRNAs have been identified that can be processed into microRNAs [86].
Of special interest in the light of biomarkers are microRNAs since it has been well established that microRNAs can regulate gene expression acting on target proteins at translational level [80, 87]. Each microRNA can have several target mRNAs; thus interaction of microRNA with the target mRNAs results in direct deregulation of different target proteins acting simultaneously in regulation of diverse cellular pathways [88, 89]. Therefore, variation in microRNA expression can result in reduced mRNA level of the targets and by this direct leading to change in protein levels within the cell [89, 90]. MicroRNAs expression patterns are tissue-specific [91] and often define the physiological nature of the cell [92]. Several publications show that altered microRNA expression in the context of several diseases (e.g. cancer, viral diseases, neurodegenerative disease, immune-related diseases) and some pathological conditions are caused by an aberrant expression level of microRNAs [93-101]. Therefore, altered microRNA expression patterns are most probably well suited as biomarkers not only for supporting cancer diagnosis but also as predictive tools to anti-cancer therapy as well as for monitoring drug resistance. Another feature is that microRNAs seem to be more robust biomarkers, having demonstrated a higher sensitivity and specificity in several studies aiming to identify cancer specific microRNAs [102].
MicroRNAs are short non-coding RNAs (18-22 nucleotides) and this characteristic offers the advantage of an increased stability in body fluids (over a gene-based mRNA detection approach). Furthermore, microRNAs seem to be associated with RNA-binding multiprotein complexes in blood [88, 103, 104] – and it has been shown that their stability is not affected by sample storage conditions [105], an important issue for exploratory studies aiming to identify novel biomarkers. Therefore, microRNAs are more suitable then other RNA based markers.
Furthermore, microRNAs could overcome the low sensitivity of traditional biomarkers -especially for early stage cancers- that is known for most of the blood-based biomarker currently in use, e.g. CA19-9 and CEA [36]. Furthermore, advances in the field of biosensor technology allowing today the linear detection of microRNA directly over a wide range of concentrations down to attomolar concentration in human serum background [106-110]. The proof-of-principle was made for detection of the cancer biomarker miR-155 in breast cancer patients [106, 111]. So it will soon be possible to develop biosensor specific for any microRNA and enable the fast and accurate measurement of the microRNA in question even if it is present in a low concentration in the blood.
The Advent of New Platforms and Technologies for Personalized Medicine
New technologies and platforms are evolving for the discovery and detection of potential new prognostic and predictive biomarkers. In this paragraph an overview will be given about some of the main technologies that have been tested over last years and their relative applications in different GI cancers for monitoring disease progression [64, 112-114], like digital-droplet PCR, next-generation sequencing, transcriptome-based platforms.
Digital-Droplet PCR (ddPCR)
The third generation of PCR, the so called ddPCR, is a PCR method for absolute quantification by counting nucleic acid molecules encapsulated in discrete, volumetrically defined, water-in-oil droplet partitions. The nucleic acid template sample is randomly distributed into these partitions, such that some droplets contain no nucleic acid template and others contain one or more copies of the template defined by a Poisson distribution [115-117]. As an end-point measurement, following PCR amplification in single droplets, ddPCR does neither require parallel amplification of any housekeeping gene for normalization for RNA based detections nor the need of standard curves generation for detection and quantification of a target DNA [115, 118-122]. Based on its high sensitivity ddPCR is often used for detecting gene copy number variations or minority targets detection such as allelic imbalance (like single-nucleotide polymorphism (SNP) and loss of heterozygosity (LOH)) and identification of rare or low level mutations in cancer [61, 62, 115, 121-124] and as independent method for verification of next-generation sequencing [61, 62, 125].
Next-Generation Sequencing (NGS)
Nowadays for NGS several different sequencing platforms have been rapidly evolving (e.g. Ion Torrent’s PGM, Pacific Biosciences’ RS and Illumina MiSeq) and the preparation of sequence libraries is specific to each platform [126, 127]. In the aforementioned case DNA pre-processing is mandatory and can be subdivided into several steps. First, extracted genomic DNA is randomly fragmented into a library of small DNA sequences (fragment size is platform specific and varies between 100 bp and 20 kbp) [128]. Then blunt-ended DNA fragments are created by an enzymatic end polishing step. Finally, specific adapters (still platform specific) are ligated to the fragments at the 3´ and 5´ends. Depending on the sequencing platform the libraries must be pre-amplified prior to sequencing or can be used directly without any amplification step [126, 129-132]. Sequencing on the generated libraries is performed in parallel by a stepwise repetition of four reactions: addition of nucleotides; washing step to remove non-incorporated nucleotides; detection of the identity of the incorporated nucleotides on each library fragment and finally a washing step that include removal of fluorescent labels or blocking reactive groups [126, 127]. Individual sequences are assembled to the reference genome and the whole-genome sequence is derived from the consensus of several aligned reads [126, 127]. The applications for NGS can span from gene expression analysis by full RNA sequencing [133-135], characterization of RNA structures [136, 137], miRNA expression [138, 139], to analysing chromatin immune precipitation (ChIP)-enriched sequences for identification of transcription factor or miRNA binding sites [140-142], DNA methylation studies [142-144] and identification of disease related genes and identification of tumour mutations for cancer personalized medicine [126, 145-152]. Of special interest is genome-wide sequencing of RNA and DNA in plasma samples for predicting responsiveness or drug resistance to anti-cancer therapy [153].
Other High-Throughput Platforms
Several commercial available MicroArrays for detection of expression of RNAs, microRNAs and long non-coding RNAs (lncRNAs) have been often used for genome-wide analysis of expression differences between normal and disease samples or to study RNA expression changes caused by substances like cytokines, growth-factors or drugs in a cell [154-158].
However, a limitation of all microarrays is that an amplification step is always necessary before the chip based measurement takes place.
Another high-throughput method to study RNA, microRNA and lncRNA expression patterns is based on the NanoString nCounter technology. This multiplexed technology detects directly the gene target expression levels without any enzymatic amplification reaction [159-161]. NanoString nCounter allows counting molecules in a given sample directly by using barcoded target 5´-end sequence-specific probes for capturing and purification as well as a barcoded 3´-end target sequence-specific fluorescent-labelled probe for detection [159-161]. Furthermore, NanoString nCounter technology can also be used for quantification of DNA, CNV and proteins [162, 163]. The advantage of this technology is that RNA and DNA, beside isolated from fresh-frozen material, can also be derived from crude tissue lysates, plasma or serum samples and formalin fixed paraffin embedded tissues [159, 160, 164].
As already mentioned GI cancer includes a heterogenous group of cancers that affect the digestive system [1, 2]. In the following part the different subgroups of GI cancer will be addressed.
Colorectal Cancer
Incidence, Diagnosis and Risk Factors
Colorectal cancer is one of the leading causes of death from cancer in Western countries [165-168]. It is the third most commonly diagnosed cancer in men and women and the fourth leading cause of cancer death worldwide [167, 169-171]. With over 63% of all cancer cases colorectal cancer is mainly a disease of developed countries with a Western culture [171, 172]. Colorectal cancer survival is highly dependent upon stage of disease at diagnosis, and the 5-year survival rate ranges from 90% for cancers detected at the localized stage to 10% for patients with metastatic disease at time of diagnosis [169, 173]. Common risk factors for colorectal cancer development are represented by: age, hereditary factors (familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC)), inflammatory bowel disease; low physical activity and excessive body weight, smoking, heavy alcohol consumption and poor nutritional practices [168-170, 172, 174-182].
Chromosomal and microsatellite instability are also involved in developing colorectal cancer especially in the case of FAP and HNPCC, respectively [182-187]. Both are hereditary genetic disorders – in the case of FAP mutations in the APC gene are present and in the case of HNPCC mutations in mismatch-repair genes (e.g. hMSH2, hMSH3, hMSH6, hMLH1, hMLH3, hPMS1, hPMS2) result in microsatellite instability [182, 188]. Microsatellite instability can be caused by a high-level CpG-island methylation phenotype and hMLH1 promoter methylation. Given the fact that it is very often associated with BRAF V600E mutation the simultaneous analysis of microsatellite instability and BRAF mutation confers an inferior prognosis [189-192]. These genetic alterations result in an increased risk to develop colorectal cancer [182, 186, 187]. Even in the case of HNPCC microRNA deregulation seems to be the key; as discussed later in this chapter over-expression of miR-155 was identified as reason for microsatellite instability by significantly down-regulating core mismatch-repair proteins [193]. This finding underlines once again the importance of microRNAs for physiological and pathological conditions as well as their potential to function as biomarkers.
Despite being an age-related disease commonly arising after 50 years, over the last years colorectal cancer diagnosed in younger people is dramatically increasing [169, 194-196].
Current Biomarkers in Use
For colorectal cancer a panel of tumour markers (CEA, CA19-9, p53, RAS, thymidine synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, deleted in colon cancer (DCC) protein and microsatellite instability) has been studied and its role in pre-operative staging and post-operative follow-up has been evaluated [36].
In the majority of colorectal cancer cases the glycoprotein CEA is over-expressed and secreted into the blood [34, 197]. Therefore the plasma level of CEA can be measured quantitatively but unfortunately due to its lack of sensitivity in early disease stages it is not recommended as a screening test for colorectal cancer [34, 36, 197]. Nevertheless, the pre-operative measurement of CEA level in patients is supportive for staging and surgical treatment planning [36]. Especially in patients who undergo resection for metastases CEA levels have prognostic value [198] and the lack of return of CEA to normal levels after surgical treatment is a marker for inadequate resection [197, 199]. The post-operative monitoring of CEA level is a useful diagnostic marker because CEA is the most frequent indicator of recurrence in asymptomatic patients and is sensitive for detecting metastases [200, 201]. Therefore, the ASCO guidelines suggest that CEA testing should be performed every 3 months in patients with stage II or III disease for at least 3 years after diagnosis given that the patient is a candidate for surgery or systemic therapy [36]. Also a systemic therapy of metastatic colorectal cancer should be monitored by measuring the level of CEA at the beginning and every 1 to 3 months during active treatment [36]. Persistently rising values above baseline suggest disease progression and require restaging [36]. However, early rise of CEA (4 to 6 weeks after treatment initiation) should not always be interpreted as an alarming sign since it can occur as treatment-induced changes in liver function, especially during oxaliplatin treatment, or can be related to other non-cancer related conditions such as gastritis, peptic ulcer disease, liver diseases and chronic inflammation [202, 203].
The role of CA19-9 as a prognostic marker in stage IV colorectal cancer patients who have undergone curative resection is supported by several studies, mainly from Asia [204-207]. Post-operative CA19-9 level seems to be an independent predictor for overall survival and the combination of elevated CEA and CA19-9 levels were positively associated with disease recurrence and lymphatic invasion [208]. But in some other studies the prognostic and predictive value of CA19-9 level was not always confirmed [205, 209, 210] and it is obviously that CA19-9 is a less sensitive biomarker than CEA [37].
Current Treatment Modalities
It is well established that aberrant epidermal growth factor receptor (EGFR) signalling is involved in the progression of colorectal cancer [211-213]. EGFR is an upstream receptor of the RAS-RAF-MEK- as well as the AKT-PI3K-pathway; both pathways resulting in cell proliferation and increased cell survival after activation [214, 215]. Therefore, blocking of EGFR is an attractive and efficient therapeutic option [214]. Cetuximab and panitumumab, are two monoclonal antibodies that prevent the activation of signal transduction pathways via EGFR binding and are approved for colorectal cancer treatment [216-219]. Unfortunately this targeted therapy against EGFR has only limited success in a specific subset of patients with metastatic colon cancer [214, 220-223].
A standard chemotherapeutic regime in the presence of distant metastases (disease stage IV) is a combined chemotherapy such as FOLFOX (folonioc acid, 5`-fluorouracil, oxaliplatin) or FOLFIRI (folonic acid, 5`-fluorouracil, irinotecan) associated with antibodies directed against EGFR (cetuximab, panitumumab) or anti-angiogenic drugs that target VEGF pathway (bevacizumab, aflibercept) [214, 224-227]. However, patients` selection for cetuximab and panitumumab treatment is based on activating mutations in the KRAS and NRAS genes (that result in permanent activation of the RAS-MEK-ERK signalling pathway) [214, 228-232]. Therefore, KRAS and NRAS are being used as biomarkers for patients` selection for the use of anti-EGFR monoclonal antibodies treatment [233-235]. Thus, only patients who are reported wild-type for mutations in RAS genes are suited for this targeted therapy [219, 236, 237].
Several clinical studies (e.g. CRYSTAL, PRIME and OPUS) have shown that patients with metastatic colorectal cancer, whose tumours contain activating mutations of RAS genes, do not derive any benefit from EGFR antibody therapy and this therapy may in fact have a detrimental effect in such patients especially if it is combined with oxaliplatin [238]. Retrospective analyses of tumours from these studies with newer methods such as next generation sequencing or BEAMing technology resulted in identification of additional mutations in 15-31% of tumours that were initially considered as RAS-wild-type and those patients had worse outcomes [238-240].
Beside mutations in the RAS genes also mutation in BRAF and PIK3CA might represent a reason for failure of the antibody based anti-EGFR therapy [228, 241, 242]. Furthermore, amplification of HER-2, MET and KRAS as well as silencing of PTEN have been recently identified as additional mechanisms that lead to failure of cetuximab and panitumumab based treatments [243-248].
Nevertheless, also patients who initially respond to the anti-EGFR antibody therapy are most likely to develop resistance within 3-12 months against the treatment [214, 220, 223, 249]. However, by using liquid biopsies it has been shown that it is possible to detect KRAS mutations 10 months before disease progression is radiologically detected [64, 214, 250-252]. This further demonstrates the power of new detection systems. Therefore, therapy can be altered earlier to prevent the progression and increase patient’s survival. Some reports have shown that it is possible to overcome the acquired resistance to anti-EGFR antibodies with a combined therapy [244, 253]. A multidrug approach that involves the use of cetuximab with the MEK inhibitor pimasertib or the MET inhibitors crizotinib resulted in restoring sensitivity to resistant tumours in some patients [244, 253]. Combination therapies however might bear the risk of higher toxicity and they could not per se improve the treatment in every patient [254, 255] and therefore combination therapies should be single patient tailored. Liquid biopsies are one possibility to monitor such treatments. First studies are underway to use cft-DNA present in the blood of colorectal cancer patients as marker for treatment response and for detection of resistance development [256, 257]. Changes in cft-DNA are in good correlation to later tumour response and therefore liquid biopsies seem to be a good prognostic tool [256].
Potential Biomarkers Currently Under Further Investigation
The first microRNAs found to be reduced in colorectal cancer patients are miR-143 and miR-145 [258]. In agreement with the outstanding role of KRAS for colorectal cancer development, KRAS has been identified as one of the miR-143 targets [259]. In the meantime, large-scale microRNA expression analyses have been performed in human colorectal cells and colon cancer patients resulting in a microRNA expression pattern for colon cancer [260, 261]. As a logical consequence, the potential of microRNAs as diagnostic markers has been suggested in the last years [154, 262-264]. Given the amount of deregulated microRNA in colon cancer it is not surprisingly that several microRNAs have been investigated as biomarkers in the context of this disease. A closer look into recent discoveries shows that microRNAs probably could allow a very distinct discrimination amongst colon cancer stages [154, 265] thus the importance of different expressed microRNAs as diagnostic markers increases further. MiR-92 has been found highly expressed in plasma of colorectal cancer patients and seems to be a promising biomarker for colorectal cancer screening tests [262-264]. For instance, in plasma of advanced colorectal cancer patients, miR-92a and miR-29a might be of diagnostic value [262, 263]. The proof-of-concept that microRNAs are also useful for monitoring the therapeutic response was provided in a cohort of colon cancer patients treated with 5´-fluorouracil and the next-generation oral 5´-fluorouracil compound S-1 [262, 266]. In this study expression of miR-181b and let-7g was significantly correlated with successful therapy [262, 266]. In HNPCC regulation of mismatch-repair proteins by miR-155 was proofed [193]. High expression of miR-155 resulted in increased microsatellite instability by reducing the expression level of MLH1, MSH2 and MSH6 [193]. A high-throughput microRNA screening revealed that miR-145 is down-regulated in tumour samples with different microsatellite status compared to healthy colorectal tissue [267]. Based on this data it was possible to associate microRNA expression levels to specific microsatellite status as well as recurrence of colorectal cancer [267]. In other studies the expression of miR-320 and miR-498 has been shown to correlate with disease-free survival [267], whereas high expression of miR-200c and miR-21 appear to be associated with poor prognosis for colorectal cancer patients [262, 268-270]. Like in many types of cancers miR-21 over-expression has been associated with low sensitivity and poor response to chemotherapy in colorectal cancer [269-271].
Recently it has been shown that a single nucleotide polymorphism in microRNA or microRNA target can be used as biomarker for survival and response to treatment for colorectal cancer patients [272, 273]. For prognosis of early-stage colorectal cancer, the single-nucleotide polymorphism rs61764370 in the let-7 complementary site 6 of KRAS mRNA was identified [273]. Furthermore, it seems possible that this single-nucleotide polymorphism could be a biomarker for the benefit from anti-EGFR antibodies based therapies in metastatic colorectal cancer [273]. In high-risk locally advanced colorectal cancer, the single nucleotide polymorphism rs4919510 in miR-608 was identified as potential diagnostic marker for disease prognosis [272].
Also lncRNAs could be useful biomarkers for colorectal cancer [274]. Two lncRNAs (HOTAIR and CRNDE) were found to be up-regulated in tumour tissue and blood of colorectal cancer patients [275, 276]. The expression level of HOTAIR correlates with the tumour stage and overall survival [275]. Therefore, detection of HOTAIR level in the blood of colorectal cancer patients could serve as additional prognostic marker [275] but it must be kept in mind that altered expression of HOTAIR is also observed in the context of other diseases e.g. gastric and pancreatic cancer [277, 278].
The most important points of the above discussion about colorectal cancer are summarized in Table 2.
Anal Cancer
Incidence, Diagnosis and Risk Factors
Cancer of anal canal makes up to 4% of all anorectal malignancies and 1.5% of gastrointestinal malignancies [165, 279-281]. But anal cancer has a significant increased incidence rate (e.g. 130% since 1970 in UK according to Cancer Research UK) particularly in human immunodeficiency virus (HIV) positive male [281]. As high risk factors causing anal cancer human papillomavirus (HPV) infection, anoreceptive intercourse, cigarette smoking, and immunosuppression, have been identified [282, 283].
Current Biomarkers in Use
Different biomarkers have been studied in squamous cell anal cancer which elucidated to some extend the cancer pathogenesis but none of them are sufficient to determine the prognosis or guide the treatment [284].
Current Treatment Modalities
In different clinical trials it was proved that anal cancer responded well to standard treatment with concurrent radio- and chemo-therapy resulting in a 60% cure rate [285-289]. Anal cancer metastasizes preferential through the lymphatic system into liver, lung and lymph nodes [290, 291].
Neither EGFR mutation nor amplification is observed in anal cancer even if sometimes EGFR is overexpressed [292, 293]. In the context of this cancer EGFR over-expression is not dictating the treatment regime [294, 295]. Surprisingly also KRAS mutations are an exception in anal cancer patients [294, 296].
Given the fact that anal cancer is often caused by HPV-infection [283, 297] it is not surprisingly that therapies used for the treatment of other HPV-related cancers (e.g. head and neck or cervical cancer [298, 299]) are also effective in anal cancer patients. Furthermore, typical consequences of HPV-infection like genomic instability, gene alterations and increased DNA damage are observed in anal cancer [300-302].
Phosphorylation and subsequent activation of AKT resulting in an increased activation of the central PI3K/AKT-signal transduction pathway also play an important role in anal cancer like in most of HPV-caused tumours [297, 303, 304].
Potential Biomarkers Currently Under Further Investigation
Anal cancer is poorly examined on molecular and biological level most probably due to the fact that it is a rare tumour with low tissue availability. No data exist about aberrant microRNA expression in anal cancer patients.
Since anal cancer is in most cases HPV-related, the cell cycle regulator p16 may serve as a biomarker for detecting HPV-DNA. Tumours with moderate to high p16 expression may respond better to chemoradiotherapy and have a lower relapse rate compared to those with low expression [290]. In a systematic review which analyzed 29 different biomarkers, only p53 and p21 were prognostic in more than one study and only p53 mutations were associated with poorer survival [305].
Up to now only one study address epigenetic differences in the context of anal cancer [306]. It was possible to identify 16 CpG sites with differentially methylation status in high-risk anal cancer patients compared to low-risk patients and by this to discriminate locally advanced from early anal cancer [306]. Therefore, it seems possible to use epigenetic alterations as potential biomarkers for stratification of anal cancer patients.
The most important points of the above discussion about anal cancer are summarized in Table 3.
Small Intestine Cancer
Incidence, Diagnosis and Risk Factors
Cancer of the small intestine is very uncommon but the incidence of small intestine cancer has increased over the last decades [165, 307-310]. Patients with Crohn’s disease, Celiac disease, Familial Adenomatous Polyposis (FAP) and Peutz-Jeghers syndrome have increased risk for developing small intestine cancer [307, 309-313]. Furthermore, some risk factors like high consumption of red or processed meat, saturated fat, obesity and smoking have been connected to this type of GI cancer [307, 311]. The prognosis for carcinomas of the small intestine is poor (5 years relative survival 30%) [165, 307, 308].
Current Biomarkers in Use
Up to now no specific biomarkers are available for predicting prognosis and treatment decision for small intestinal cancer.
Current Treatment Modalities
Because of the low prevalence the efficacy of chemotherapy for treating small intestine cancer is only addressed in limited studies with small patient numbers [314-320]. Treatment with 5-fluorouracil of advanced small intestine cancer patients results in median survival of 9-13 months [314-316]. Recently it was demonstrated that curative resection and definitive chemotherapy for unresectable cases of small intestine cancer can be an effective treatment approach [317, 321].
Potential Biomarkers Currently Under Further Investigation
Furthermore, only few studies have been performed to analyze genetic differences and aberrant microRNA expression in small intestine cancer.
One study based on 46 patients showed that small intestine cancer can be subdivided into microsatellite instable and microsatellite stable tumours [322]. Patients with chromosomal stable small intestine cancer were found to have low frequencies of altered CpG island methylation, rarely BRAF mutations but often mutations in KRAS gen [322].
The most important points of the above discussion about small intestine cancer are summarized in Table 4.
Gastric Cancer
Incidence, Diagnosis and Risk Factors
Gastric cancer also known as stomach cancer was the most common cancer less than a century ago [323, 324]. Since the widespread use of refrigerators the rate of gastric cancer decreased [325]. Beside increased consumption of fresh vegetables and fruits the intake of salt, which had been used as a food preservative, decreased. Furthermore also food contaminations caused by carcinogenic compounds arising from unrefrigerated meat products have been strongly decreased [325]. Although it is no longer the most common cancer worldwide, every year approximately 990,000 people are still diagnosed with gastric cancer worldwide, of whom about 738,000 die from cancer [323, 324, 326]. Currently, as incidence, gastric cancer is the fourth most common cancer and the second leading cause of cancer death worldwide [165, 323, 327]. The high mortality is caused by the fact that gastric cancer often forms metastasis [328]. The highest incidence rates are observed in East Asia, East Europe, and South America, whereas the lowest rates are observed in North America and most parts of Africa [323, 329].
Gastric cancer can be subdivided into two subgroups: an intestinal and a diffuse type [330-332]. Intestinal tumours progress in sequential steps starting with atrophic gastritis followed by intestinal metaplasia then dysplasia and finally cancer [331, 332]. Diffuse gastric cancer is only related on chronic gastritis associated with Helicobacter pylori (H. pylori) infection [331, 332].
In a small subgroup of gastric cancer patients (up to 3%) hereditary diffuse gastric cancer (HDGC) is diagnosed [333]. Mutations in the E-cadherin gene are known to cause HDGC [334].
Current Treatment Modalities
Surprisingly incidence rates of gastric cancer are found to be 2- to 3-folds higher in men than in women [323, 326, 335]. The prognosis for carcinomas of the stomach is poor (5 years relative survival 30%) [165]. Nevertheless, in patients’ receiving perioperative chemotherapy before operation 5-year survival was found to be 36% [336] and for advanced or metastatic gastric cancer the 5-year survival is around 5-20% with median overall survival being less than 12 months [337-339].
Best survival results are achieved with a combined chemotherapy composed of 5`-fluorouracil and cis-platin in combination with an anthracycline [340, 341].
Current Biomarkers in Use
Based on several studies showing over-expression or amplification of human epidermal growth factor receptor-2 (HER-2 or ERBB2) in up to 30% of gastric tumours it becomes more and more reasonable to recognize HER-2 as an important biomarker and key driver in gastric cancer [340, 342-349]. The HER-2 positivity rate in gastric tumours is very similar to HER-2 positive breast cancer cases [350, 351]. Based on the good tolerability profile of the HER-2 antibody trastuzumab in patients with breast cancer [352, 353] trastuzumab was also introduced into the treatment of gastric cancer patients [340, 345]. In one large international multicenter study it was shown that addition of trastuzumab to the standard combination chemotherapy significantly improved overall survival compared with chemotherapy alone in advanced gastric cancer [345]. But up to now it is not finally sorted out if the observed positive trastuzumab effect is merely based on the fact that HER-2 expression is more common found in patients with intestinal-type tumours that are known to have a better clinical outcome compared to gastric cancer patients with diffuse-type tumours [344, 354-357]. Nevertheless, in several studies were demonstrated that HER-2-positive gastric tumours are a more aggressive cancer subgroup and resulting in poor outcome like it is the case in HER-2-positive breast cancer [342, 344, 358, 359]. Therefore, further studies are an urgent need to clarify if HER-2 expression has a good or poor prognosis in gastric cancer.
Potential Biomarkers Currently Under Further Investigation
Also in gastric cancer the first attempts have been done to use cft-DNA for monitoring the disease status [360, 361]. In a small gastric cancer patient cohort the concentration of cft-DNA was found to increase in parallel with established serological biomarkers but cft-DNA has not had advantage over serological biomarkers already in use [360].
Gastric cancer is characterized by numerous genetic and epigenetic alterations. A variety of different genetic and epigenetic changes are involved in and favour development of gastric cancer [362, 363]. Loss of the APC tumour suppressor gene, ß-catenin and K-ras mutations as well as inactivation of TP53 tumour suppressor gene are often found in gastric cancer patients [362, 364-366]. Also c-met and HER-2 (already discussed above) gene amplifications are often observed [362, 367-371]. Furthermore CpG-hypermethylation of hMLH1 mismatch repair gene resulting in microsatellite instability is a common event in gastric cancer [330, 362, 372-377]. Beside hypermethylation, also increased rate of hypomethylation can be a reason for cancer as it was shown for the oncogenes ELK1, FRAT2, r-RAS, RHOB, and RHO6 that are found to be activated by demethylation of specific CpG sites in more than half of gastric cancers [378, 379].
